Matinas BioPharma Selected to Present at Cavendish Global Health Impact Forum
Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences
BEDMINSTER, N.J., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective therapeutics for the treatment of serious and life-threatening infections, today announced that it has been selected as a Cavendish Innovation Partner and will present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic, which takes place October 25th to October 28th at The Cleveland Clinic, Cleveland, Ohio.
The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, research institutions, and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year. The next Forum is being co-hosted by The Cleveland Clinic and Cleveland Clinic Innovations.
Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, “The theme of our Cleveland Clinic hosted Forum is a ‘Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.’ With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Matinas BioPharma’s research and scientific insights in the utilization of lipid-crystal, nanoparticle cochleate drug formulations have the potential to transform the way potent medicines are administered, providing physicians and patients with more tolerable, safer, effective and powerful anti-infective options and positions them to make a major contribution to the battle against the growing global multi-drug resistant ‘superbug’ public health threat.”
“We are honored to be selected as a Cavendish Global Innovation Partner and to present at this unique event,” added Jerome D. Jabbour, Co-Founder and Chief Business Officer of Matinas BioPharma. “Our selection is further recognition of our innovative approach to nano-encapsulating existing drugs to formulate safe and effective broad spectrum anti-infective therapies to treat serious and life-threatening infections on a global basis. We welcome this opportunity to introduce our disruptive and potentially transformational products and platform technology to many of world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”
Cavendish Global consists of over 200 leading family offices and foundations from around the world with combined assets of over $260 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.
About Cavendish Global
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; the next Forum is being co-hosted by The Cleveland Clinic and Cleveland Clinic Innovations.
For more information: http://cavendishglobal.com.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections. The Company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead drug candidate is MAT2203, an orally-administered, encochleated formulation of amphotericin B (a broad spectrum fungicidal agent). The Company also intends to file an investigational new drug application (IND) for MAT2501, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for gram-negative and intracellular bacterial infections. In addition, the Company is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoproteins and PCSK9 levels.
The Company's lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology.
For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.
Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's strategic focus and the future development of its product candidates, including MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the Company’s ability to identify and pursue development and partnership opportunities for its MAT9001 on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to maintain and derive benefit from the Qualified Infectious Disease Product (QIDP) and Fast Track designations for MAT2203, which does not change the standards for regulatory approval or guarantee regulatory approval on an expedited basis, or at all; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.
Cavendish Global Contact Alex Charlton President, Cavendish Global Phone: +1-917-576-1435 Email: alex.charlton@cavendishglobal.com Matinas BioPharma Investor Contact Jenene Thomas Jenene Thomas Communications, LLC Phone: +1 (908) 938-1475 Email: jthomas@matinasbiopharma.com Matinas BioPharma Media Contact: David Connolly LaVoieHealthScience Phone: +1 (617) 374-8800 Email: dconnolly@lavoiehealthscience.com
Released October 22, 2015